Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The accelerated review covers WCK 5222 for multiple critical infections
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Subscribe To Our Newsletter & Stay Updated
